A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy andsafety of zanidatamab in combination with physician’s choice chemotherapy compared totrastuzumab in combination with physician’s choice chemotherapy for the treatment ofparticipants with metastatic HER2-positive breast cancer who have progressed on, or areintolerant to, previous trastuzumab deruxtecan treatment
Condition: Metastatic HER2-Positive Breast Cancer
Study Number: JZP598-303 - Protocol and Amendment Number: JZP598-303-02
Drugs: Zanidatamab
Phase: 3